Arcutis Biotherapeutics, Inc. (ARQT)

Arcutis Biotherapeutics Financials Overview

Financials in millions USD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue Revenue Growth	463.98	376.07	196.54	59.61	3.69	-
Revenue Growth	76.11%	91.34%	229.73%	1517.09%	-	-
Gross Profit Gross Profit Growth	422.89	339.38	177.41	54.62	2.93	-
Operating Income Operating Income Growth	34.25	-12.23	-128.4	-241.1	-301.63	-206.53
Net Income Net Income Growth	28.52	-16.14	-140.04	-262.14	-311.46	-206.36
Earnings Per Share EPS Growth	0.22	-0.13	-1.16	-3.78	-5.66	-4.18
EPS Growth	-	-	-	-	-	-

Revenue by Segment

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
ZORYVE Cream 0.3% ZORYVE Cream 0.3% Growth	137.93	121	85.08	29.19	3.69
ZORYVE Foam ZORYVE Foam Growth	229.44	181.89	71.54	-	-
ZORYVE Cream 0.15% ZORYVE Cream 0.15% Growth	89.41	68.27	9.92	-	-
ZORYVE Cream 0.05% ZORYVE Cream 0.05% Growth	-	0.91	-	-	-
Other Segment Other Segment Growth	-	4	30	30.42	-
Revenue (Total) Revenue (Total) Growth	463.98	376.07	196.54	59.61	3.69

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Investments Cash & Investments Growth	238.55	220.98	227.96	271.86	409.59	387.06
Total Debt Total Debt Growth	114.14	114.52	109.77	205.92	202.54	77.56
Net Cash (Debt) Net Cash Growth	124.42	106.46	118.19	65.95	207.05	309.5
Net Cash Growth	54.25%	-9.92%	79.22%	-68.15%	-33.10%	10.74%
Net Cash Per Share Net Cash Per Share Growth	0.94	0.84	0.98	0.95	3.76	6.26

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow Operating Cash Flow Growth	39.31	-5.63	-112.16	-247.06	-257.72	-174.63
Capital Expenditures CapEx Growth	-0.16	-0.69	-0.14	-0.43	-0.33	-1
Free Cash Flow Free Cash Flow Growth	39.15	-6.31	-112.3	-247.49	-258.05	-175.62
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Gross Margin	91.14%	90.24%	90.27%	91.63%	79.54%	-
Operating Margin	7.38%	-3.25%	-65.33%	-404.49%	-8183.04%	-
Pretax Margin	6.31%	-3.98%	-70.92%	-434.57%	-8449.76%	-
Profit Margin	6.15%	-4.29%	-71.25%	-439.79%	-8449.76%	-
FCF Margin	8.44%	-1.68%	-57.14%	-415.20%	-7000.76%	-

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 4, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Forward PE	33.96	76.62	-	-	-	-
PS Ratio	6.47	9.46	8.30	5.11	244.56	-

Data Sources: S&P Global Market Intelligence and Fiscal.ai Last updated: Aug 5, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company. Revenue segment data is provided by Fiscal.ai.

Update frequency:

Quarterly

Last checked:

Sep 4, 2026

Data Sources Report a data error